Top reasons for recalls include software, quality and parts issues.
The challenge for the digital health community will be to bring the same high standards for care in the physical world to their digital interactions.
A review of new, successful treatment options for the novel coronavirus.
The absence of any of these disciplines can lead to blind spots that can introduce risk, but they are not all created equal.
No longer just “the big company advantage,” CM&S is an accepted and viable device industry path to market for large and small medical device makers alike.
Lucira Health’s single-use molecular test kit will be available for prescription home use in people age 14 and older.
All commercial, clinical, R&D and manufacturing activities surrounding the product will end.
Moving too quickly in the product development process can lead to mistakes.
An upcoming webinar will discuss the new methods and protocols that have emerged as a result of conducting trials and HF studies during the pandemic.
And medtech companies need to keep interoperability and security top of mind.